Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379587 · ClinicalTrials.gov registry record · Phase 1
Rituximab for Prevention of Chronic GVHD
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00379587 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 65 participants.
The verdict
NCT00379587, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD. Chronic GVHD is a medical condition that can occur after bone marrow or stem cells are transplanted form one individual to another. After the transplant, the donor immune system may recognize the recipient body as foreign and may attempt to "reject" the body. Rituximab is a drug that interferes with the immune system function by specifically targeting B cells and killing them.
Interventions
- DRUG Rituximab
- DRUG 375 mg/m2 RRituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379587
The ClinicalTrials.gov registry entry for NCT00379587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00379587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00379587 about?
NCT00379587 is a clinical study titled "Rituximab for Prevention of Chronic GVHD". The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD. Chronic GVHD is a medical condition that can occur after bone marrow or stem cells are transplanted form one individual to another. After the ...
What is the current status of trial NCT00379587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2006-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00379587?
The interventions under investigation include: Rituximab (DRUG), 375 mg/m2 RRituximab (DRUG).
Who is sponsoring clinical trial NCT00379587?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.